New antifungal pill passes first safety check in small study
NCT ID NCT02957929
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 27 times
Summary
This early-stage study tested a new oral drug called APX001 in 46 healthy volunteers to see if it is safe and how the body handles it. Some participants received the drug and others received a placebo (a dummy pill). The study also looked at how food affects the drug and whether it interacts with other medications. The goal was to gather initial safety information, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FUNGAL INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
PRA Health Sciences
Groningen, Netherlands
-
PRA Health Sciences (PRA) - Early Development Services (EDS)
Groningen, 9728 NZ, Netherlands
Conditions
Explore the condition pages connected to this study.